Newsfeeds - Spark Newswire

2 minute read

Lantern Pharma Receives Pre-IND Feedback From The FDA, Clearing A Path For Drug Candidate LP-184’s Phase 1 Clinical Trial In Q2 2023

Today, 8:08 AM

Lantern Pharma Inc. (NASDAQ:LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") and machine learning (“M.L.”) platform to transform the

LTRN

2 minute read

Lantern Pharma Announces Data Highlighting The Anti-Tumor Potency Of Drug Candidate LP-184 For Glioblastoma At The Society For Neuro-oncology Annual Meeting

By Benzinga Newsdesk

Today, 8:08 AM

Lantern Pharma Inc. (NASDAQ:LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") and machine learning (“M.L.”) platform to transform the

LTRN

13 minute read

Earnings

Earnings Scheduled For November 7, 2022

By Benzinga Insights

Today, 8:08 AM

Companies Reporting Before The Bell • NAPCO Security Techs (NASDAQ:NSSC) is expected to report quarterly earnings at $0.13 per share on revenue of $36.34 million.

AAON

1 minute read

Earnings

Earnings Preview: Lantern Pharma

By Benzinga Insights

Today, 8:08 AM

Lantern Pharma (NASDAQ:LTRN) is set to give its latest quarterly earnings report on Monday, 2022-11-07. Here's what investors need to know before the announcement. Analysts estimate that Lantern Pharma will report an earnings per share (EPS) of $-0.54.

LTRN

1 minute read

EF Hutton Initiates Coverage On Lantern Pharma with Buy Rating, Announces Price Target of $11

By Benzinga Newsdesk

Today, 8:08 AM

EF Hutton analyst Michael King initiates coverage on Lantern Pharma (NASDAQ:LTRN) with a Buy rating and announces Price Target of $11.

LTRN

6 minute read

Options

Stocks That Hit 52-Week Lows On Thursday

By Benzinga Insights

Today, 8:08 AM

On Thursday, 111 stocks hit new 52-week lows.

ADIL

1 minute read

Legal
News

Lantern Pharma Announces Issuance Of New Patent That Strengthens Patent Portfolio For Cancer Drug Candidate LP-300

By Benzinga Newsdesk

Today, 8:08 AM

U.S. Patent No. 11,471,431 relates to the use of LP-300 to increase the survival time of patients with cancers overexpressing thioredoxin or glutaredoxin. The patent issuance extends commercial protection for uses of

LTRN

2 minute read

Lantern Pharma to Present Preclinical Data On The Efficacy Of LP-284 For Mantle Cell Lymphoma At The Society Of Hematologic Oncology Annual Meeting September 28

By Benzinga Newsdesk

Today, 8:08 AM

Lantern Pharma Inc. (NASDAQ:LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") and machine learning ("M.L.") platform to

LTRN

56 minute read

Options

Stocks That Hit 52-Week Lows On Thursday

By Benzinga Insights

Today, 8:08 AM

On Thursday, 1076 companies hit new 52-week lows.

$APE

1 minute read

Earnings

Recap: Lantern Pharma Q2 Earnings

By Benzinga Insights

Today, 8:08 AM

Lantern Pharma (NASDAQ:LTRN) reported its Q2 earnings results on Monday, August 8, 2022 at 04:00 PM. Here's what investors need to know about the announcement.

LTRN